In conclusion, the present results suggest that the protective effect of paeoniflorin in NAFLD treatment may result from insulin-sensitizing effects though the regulation of the IRS1/Akt/GSK3β pathway and from reduced ROS production through the suppression of CYP2E1. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.